Key points are not available for this paper at this time.
You have accessJournal of UrologyProstate Cancer: Detection p=0.02) on multivariable analysis. Compared to white patients, black patients also had lower odds ratio for genetic testing (OR: 0.09; p=0.03). There were no differences in using genomic testing for surgery versus radiation therapy (OR 1.76; p=0.36). CONCLUSIONS: Over the last decade, the use of genomic testing at the time surgery or radiation therapy for localized prostate cancer remains low and underutilized. Older and black patients were far less likely to receive genetic testing at the time of primary therapy to help inform treatment decisions. Further study is needed to analyze genomic testing use and its role in clinical decision making as it pertains to prostate cancer. Source of Funding: Schramm Foundation © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e511 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Brett Wiesen More articles by this author Justin Achua More articles by this author Adam Warren More articles by this author Badrinath Konety More articles by this author Tyler Robin More articles by this author Boris Gershman More articles by this author Thomas Flaig More articles by this author Corbin Eule More articles by this author Simon Kim More articles by this author Expand All Advertisement PDF downloadLoading ...
Wiesen et al. (2024) studied this question.